Windtree Therapeutics, Inc. hopes eventually to bring its first-in-class SERCA 2a activator istaroxime to market for treatment of acute heart failure, but along the way to getting potentially approvable data for that indication it determined that another cardiovascular setting, early cardiogenic shock (ECS), could offer a simpler, less expensive means for getting the drug on the market.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?